Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT®.TB Test
OXFORD, United Kingdom and MARLBOROUGH, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it applauds updated guidelines from the American Academy of Pediatrics (AAP) on screening for latent
View HTML
Toggle Summary Oxford Immunotec Announces Data Presentations for T-SPOT®.CMV Test at the 2018 American Transplant Congress
OXFORD, United Kingdom and MARLBOROUGH, Mass. , June 04, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that data from studies utilizing the T-SPOT. CMV test will be presented at the American Transplant Congress (ATC)
View HTML
Toggle Summary Oxford Immunotec to Present at the Jefferies 2018 Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 29, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Rick Altieri , Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference on Tuesday,
View HTML
Toggle Summary Oxford Immunotec’s T-SPOT®.TB Test Included in the World Health Organization’s First-Ever Essential Diagnostics List
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company’s T-SPOT. TB test for tuberculosis (TB) infection has been included in the World Health
View HTML
Toggle Summary Oxford Immunotec to Present at the 2018 UBS Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, will present at the 2018 UBS Global Healthcare Conference
View HTML
Toggle Summary Oxford Immunotec Reports First Quarter 2018 Financial Results
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced first quarter 2018 financial results. “Our first quarter results were in line with our expectations, with
View HTML
Toggle Summary Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2018 financial results prior to market open on Tuesday, May 1 , 2018.  Dr.
View HTML
Toggle Summary Oxford Immunotec to Present at Two Upcoming Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass. , March 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, is scheduled to present at the following upcoming
View HTML
Toggle Summary Oxford Immunotec Announces Appointment of Mark Klausner to the Board of Directors
OXFORD, United Kingdom and MARLBOROUGH, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the appointment of Mark Klausner to the Company's Board of Directors. Mr.
View HTML
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results
2017 marks the 13 th consecutive year of at least 20% year-over-year constant currency revenue growth >25% pro forma organic growth for the year in tick-borne disease and other revenue Balance sheet strengthened by December patent infringement settlement, which included a cash receipt of $27.5
View HTML